KLRK1 and acute lymphoblastic leukemia: The miR-29 is also identified being downregulated in NK cells in patients with T-cell acute lymphoblastic leukemia (T-ALL), with a reduction in IFN-γ production as well as NK group 2D (NKG2D) expression, who is one of the major activating receptors of NK cells binding to its ligands that are expressed on malignant cells, accompanied by accelerated ALL progression and decreased survival time [226, 227].